Total contact casting

Last updated

Total contact casting (TCC) is a specially designed cast designed to take weight off of the foot (off-loading) in patients with diabetic foot ulcers (DFUs). Reducing pressure on the wound by taking weight off the foot has proven to be very effective in DFU treatment. DFUs are a major factor leading to lower leg amputations among the diabetic population in the US with 85% of amputations in diabetics being preceded by a DFU. [1] Furthermore, the five-year post-amputation mortality rate among diabetics is estimated at 45% for those with neuropathic DFUs. [1]

Contents

TCC has been used for off-loading DFUs in the US since the mid-1960s and is regarded by many practitioners as the "reference standard" for off-loading the bottom surface (sole) of the foot. [2]

TCC involves encasing the patient's complete foot, including toes, and the lower leg in a specialist cast that redistributes weight and pressure in the lower leg and foot during everyday movements. This redistributes pressure from the foot into the leg, which is more able to bear weight, to protect the wound, letting it regenerate tissue and heal. [3] TCC also keeps the ankle from rotating during walking, which prevents shearing and twisting forces that can further damage the wound. [4]

Effective off-loading is a key treatment modality for DFUs, particularly those where there is damage to the nerves in the feet (peripheral neuropathy). Along with infection management and vascular assessment, TCC is vital aspect to effectively managing DFUs. [4] TCC is the most effective and reliable method for off-loading DFUs. [5] [6] [7]

History of clinical use

The use of TCC for foot ulcers resulting from leprosy (Hansen's disease) was reported by Joseph Khan in India in the 1930s. [8] Research conducted by Paul W. Brand, MD, in the 1940s and 50s, also in India, demonstrated that the wounds in the feet were caused by nerve damage (neuropathy) rather than infection, as previously thought. In his use of TCC to eliminate weight and pressure on the ulcers, he observed the healing of ulcers that had been present for a long time. These seminal observations resulted in the development of treatments to manage neuropathic foot ulcers, which are useful for patients with diabetes. [9]

In 1965, TCC was introduced to the United States by Dr. Brand, then at the National Hansen's Disease Center in Carville, Louisiana. The goal of TCC was to distribute weight over the entire foot and lower leg. [8] Over time, the staff at Carver Hospital refined the method to reduce the development of other wounds that occur in part because of the initial problem with the foot (secondary ulceration).

Materials have changed over the years, from an unmodified plaster of Paris, to formulations containing fiberglass. However, plaster of Paris casts take too long to fully dry and limits patient mobility for up to 74 hours — if the patient walks on the cast during this time, the shape will change, and the cast will not protect the foot and wound correctly. [10] Fiberglass casts were introduced in the 1980s or 1990s. The curing time of a fiberglass cast is far shorter than plaster of Paris, letting the patient walk with an outer boot within an hour of application. Because casts made of fiberglass have lower breakdown rate and do not impede patient mobility, this material has become the choice for TCC. [11] [12]

In 2003, the first TCC casting system that contained all the materials in one package (MedE-Kast Total Contact Casting System) was developed. This innovation helped standardize the application of TCC. Other advancements have been made to make casting easier to learn, easier to apply and less time-consuming.

In 2008, the TCC-EZ Total Contact Casting system became available. In addition to the established benefits of traditional TCC, TCC-EZ also provided an easy to apply casting sock. The one-piece, roll-on, woven design simplified the application process. This cast can be put on in less than ten minutes. The ease of use of TCC EZ has been a driver in the growth of TCC use and has helped increase the accessibility and administration of effective off-loading. [13]

However, despite the availability of specialist kits, there still exists a large "gap in practice" between the accepted gold standard of care and the number of patients currently treated with this standard of care. The US Wound Registry (USWR) data from 2007 to 2013 shows that of 11,784 patients treated for DFUs, only 16% received TCC. [14]

Figure 1 -- DFUs caused by pressure, shear and repetitive stresses Physical causes of diabetic foot ulcers.png
Figure 1 — DFUs caused by pressure, shear and repetitive stresses

Diabetic foot ulcer overview

Neuropathic DFUs are chronic wounds that result from a combination of factors. Some of the main factors that result in DFUs include (Figure 1):

  1. Excessive direct pressure (for example, the weight on the feet that naturally results from standing)
  2. Shear (usually twisting forces between the skin and footwear)
  3. Repetitive stresses (for example, from walking)
  4. Peripheral neuropathy (damage to the nerves in the feet). [4]

These factors rarely cause problems in healthy people but the accompanying neuropathy means that the "pain feedback loop" that induces humans to limp or keep their weight off an injury no longer functions properly in diabetic patients. [15] The result is that pressure and abrasion injuries, such as bruising and blisters caused by poor footwear, are not noticed and often ignored, and the continual use of the limb disrupts and damages the healing process.

The healing of DFUs requires many weeks, and patients need to be effectively off loaded during this time. A recent publication on the treatment of DFUs identified that the largest potential improvement in DFU care would come about through adoption of effective off-loading techniques. [4]

Explanation of off-loading techniques

Effective off-loading is not simple, especially because of the extensive healing time often required. Most patients need to remain mobile to continue with daily life, therefore enforced restrained bed rest or sedation are neither convenient nor recommended methods to achieve effective off loading. Instead, various non constraining off-loading methods, from bed rest, crutches and wheelchairs, to complex fixed and removable boots are used to allow the patient continued movement. [4]

Other than bed rest, wheelchairs and crutches, none of which are supported by published clinical evidence as effective methods, [4] off-loading devices (Figure 2) can be functionally classified into two groups:

Figure 2 -- Examples of off-loading devices Examples of foot off-loading devices.jpg
Figure 2 — Examples of off-loading devices

A recent Cochrane review of off-loading devices found that non-removable, pressure-reducing casts were the most effective off-loading devices for DFUs. [7] Although another recent review of the efficacy of different off-loading techniques and devices highlighted a paucity of clinical evidence for many. [4]

Pressure is a major issue for patients with diabetes and an even greater challenge for those who are also obese, because each step taken increases the pressure of bodyweight on each foot by 2 to 2.5 times. [4] It is, therefore, necessary to slow down the rhythm and speed of walking of the patient and reduce the strain rate (defined as force divided by time). [4]

Immobilization of the ankle joint reduces pressure in the forefoot and plantar regions from the propulsion phase of walking, which occurs during forward motion. Both TCCs and removable cast walkers can immobilize the ankle, but TCC ensures constant use by the patient. [4]

TCC reduces the stride length, which slows down the foot and reduces the force applied to the foot. [16] TCC has been shown to reduce plantar pressure by 32%, 63%, and 69% on the fifth, fourth, and first metatarsal heads, respectively; 65% on the great toe; and 45% on the heel. [17] TCC can be used to off-load the heel, but a panel of experts agreed that this approach might not be as effective as for off-loading of forefoot ulcers. [4]

Clinical evidence for total contact casting

The use of TCC as the most effective off-loading method is strongly supported by clinical evidence. Randomized clinical trials provide strong evidence of reduced healing time and greater numbers of healed DFUs for TCC when compared to other methods. [5] [18] [19] [20] [21] [22] [23] [24]

Lavery et al. (2014) showed that TCC had a wound closure rate of 88.9%, compared to 50% for healing sandal and 40% for shear-reducing walking boot. They also showed that median time to healing for TCC was 5.4 weeks, compared to 8.9 weeks for a healing sandal and 6.7 weeks for sheer reducing walking boot.

Armstrong et al. (2001) determined that TCC had a healing rate of 88.9%, compared to 65% for a removable cast walker and 58.3% for a half-shoe, and time to healing was least for TCC at 4.8 weeks, compared to 7.2 weeks for the removable cast walker and 8.7 weeks for the half-shoe. This data was reiterated by Lavery almost 14 years later in a newer study (Figure 3). [25]

Figure 3 -- Randomized, controlled clinical trial from 2014, comparing total contact casting (TCC), healing sandal (HS) and shear-reducing walking boot (SRB). Data replotted from Lavery et al. 2014. Comparison of off-loading devices.jpg
Figure 3 — Randomized, controlled clinical trial from 2014, comparing total contact casting (TCC), healing sandal (HS) and shear-reducing walking boot (SRB). Data replotted from Lavery et al. 2014.

New technology

There are four options currently available for total contact casting.

Derma Sciences' TCC-EZ Total Contact Cast (acquired by Integra LifeSciences in 2017) treats diabetic foot wounds by reducing pressure and providing additional support. [26] [27] TCC-EZ's woven, prefabricated material rolls onto a patient's leg and reduces application time compared to a conventional total contact cast. [28]

Another new system, TrueKast, has a built in saw for ease in removal. [29] This can prevent forced compliance from the patient and is also risky. Many experienced physicians are concerned putting a saw blade in-between a patient's skin and a hardened layer of fiberglass. Many patients with DFU's have peripheral neuropathy and poses a serious potential hazard.

BSN Medicals' Cutimed (acquired by Svenska Cellulosa Aktiebolaget in 2016) is a traditional fiberglass total contact cast system utilizing top-of-the-line BSN cast tape. [30]

M-Medical provides a traditional fiberglass total contact cast system with patented padding protection preventing iatrogenic lesions. One size fits all.

Complications

Total contact casting is contraindicated in the presence of untreated infection or osteomyelitis and in patients with severe peripheral arterial disease. It should be used with caution in deep or heavily draining wounds and in ataxic, blind or severely obese patients. Patient compliance is also necessary to minimize complications. Patients may require assistance with activities of daily living, such as bathing and sleeping. A TCC may also interfere with the operation of a motor vehicle, and patients should be counseled not to drive if the cast is on the right leg. Moreover, any advanced wound-healing adjunctive therapies that require daily applications may not be suitable for use with patients using a non removable device, such as the TCC. [4] In addition, TCC may cause or exacerbate deformed toenails, ischemia, fungal infection, dermatitis, and claustrophobia. [31] [32] In situations requiring prolonged casting, joint rigidity and muscular atrophy have been documented. The patient should also be advised that certain designs of TCCs might exacerbate postural instability. [4]

Overall, clinical evidence strongly supports the use of TCC in the treatment of DFUs, and the high efficacy of TCC comes with low risk of major complications. TCC should therefore continue to be the gold standard for the treatment of DFUs. [33]

Related Research Articles

<span class="mw-page-title-main">Ulcer (dermatology)</span> Type of cutaneous condition

An ulcer is a sore on the skin or a mucous membrane, accompanied by the disintegration of tissue. Ulcers can result in complete loss of the epidermis and often portions of the dermis and even subcutaneous fat. Ulcers are most common on the skin of the lower extremities and in the gastrointestinal tract. An ulcer that appears on the skin is often visible as an inflamed tissue with an area of reddened skin. A skin ulcer is often visible in the event of exposure to heat or cold, irritation, or a problem with blood circulation.

Diabetic neuropathy is various types of nerve damage associated with diabetes mellitus. Symptoms depend on the site of nerve damage and can include motor changes such as weakness; sensory symptoms such as numbness, tingling, or pain; or autonomic changes such as urinary symptoms. These changes are thought to result from a microvascular injury involving small blood vessels that supply nerves. Relatively common conditions which may be associated with diabetic neuropathy include distal symmetric polyneuropathy; third, fourth, or sixth cranial nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; and autonomic neuropathy.

<span class="mw-page-title-main">Neuropathic arthropathy</span> Medical condition

Neuropathic arthropathy, also known as Charcot joint after the first to describe it, Jean-Martin Charcot, refers to progressive degeneration of a weight-bearing joint, a process marked by bony destruction, bone resorption, and eventual deformity due to loss of sensation. Onset is usually insidious.

<span class="mw-page-title-main">Maggot therapy</span> Wound care by maggot therapy

Maggot therapy is a type of biotherapy involving the introduction of live, disinfected maggots into non-healing skin and soft-tissue wounds of a human or other animal for the purpose of cleaning out the necrotic (dead) tissue within a wound (debridement), and disinfection.

A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do; wounds that do not heal within three months are often considered chronic. Chronic wounds seem to be detained in one or more of the phases of wound healing. For example, chronic wounds often remain in the inflammatory stage for too long. To overcome that stage and jump-start the healing process, a number of factors need to be addressed such as bacterial burden, necrotic tissue, and moisture balance of the whole wound. In acute wounds, there is a precise balance between production and degradation of molecules such as collagen; in chronic wounds this balance is lost and degradation plays too large a role.

<span class="mw-page-title-main">Negative-pressure wound therapy</span> Therapeutic technique

Negative-pressure wound therapy (NPWT), also known as a vacuum assisted closure (VAC), is a therapeutic technique using a suction pump, tubing, and a dressing to remove excess exudate and promote healing in acute or chronic wounds and second- and third-degree burns. The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment using a sealed wound dressing connected to a vacuum pump. The use of this technique in wound management started in the 1990s and this technique is often recommended for treatment of a range of wounds including dehisced surgical wounds, closed surgical wounds, open abdominal wounds, open fractures, pressure injuries or pressure ulcers, diabetic foot ulcers, venous insufficiency ulcers, some types of skin grafts, burns, sternal wounds. It may also be considered after a clean surgery in a person who is obese.

"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties. WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection. Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie. The chemical formula is given as Cl4H2O114-. This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O114-" = 4ClO2− + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite.

Becaplermin is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. It is also known as "platelet-derived growth factor BB".

<span class="mw-page-title-main">Pedobarography</span> Study of pressure fields between foot and a supporting surface

Pedobarography is the study of pressure fields acting between the plantar surface of the foot and a supporting surface. Used most often for biomechanical analysis of gait and posture, pedobarography is employed in a wide range of applications including sports biomechanics and gait biometrics. The term 'pedobarography' is derived from the Latin: pedes, referring to the foot, and the Greek: baros meaning 'weight' and also 'pressure'.

<span class="mw-page-title-main">Diabetic shoe</span> Shoes intended to reduce the risk of skin breakdown in diabetics

Diabetic shoes are specially designed shoes, or shoe inserts, intended to reduce the risk of skin breakdown in diabetics with existing foot disease and relieve pressure to prevent diabetic foot ulcers.

<span class="mw-page-title-main">Arterial insufficiency ulcer</span> Medical condition

Arterial insufficiency ulcers are mostly located on the lateral surface of the ankle or the distal digits. They are commonly caused by peripheral artery disease (PAD).

Transdermal Continuous Oxygen Therapy is a wound closure technique for chronic and acute wounds which blankets a wound in oxygen on a 24-hour basis until the wound heals. Unlike hyperbaric oxygen treatment for chronic wounds, oxygen treatment used in this therapy is not systemic in nature and treats only the wound area. This treatment differs from topical oxygen treatments, as topical oxygen typically involves sporadic treatments of 1–3 hours several times per week, while TCOT treatment is 24/7 by nature.

Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.

<span class="mw-page-title-main">Diabetic foot</span> Medical condition

A diabetic foot disease is any condition that results directly from peripheral artery disease (PAD) or sensory neuropathy affecting the feet of people living with diabetes. Diabetic foot conditions can be acute or chronic complications of diabetes. Presence of several characteristic diabetic foot pathologies such as infection, diabetic foot ulcer and neuropathic osteoarthropathy is called diabetic foot syndrome. The resulting bone deformity is known as Charcot foot.

Chronic wound pain is a condition described as unremitting, disabling, and recalcitrant pain experienced by individuals with various types of chronic wounds. Chronic wounds such as venous leg ulcers, arterial ulcers, diabetic foot ulcers, pressure ulcers, and malignant wounds can have an enormous impact on an individual’s quality of life with pain being one of the most distressing symptoms.

<span class="mw-page-title-main">Diabetic foot ulcer</span> Medical condition

Diabetic foot ulcer is a breakdown of the skin and sometimes deeper tissues of the foot that leads to sore formation. It may occur due to a variety of mechanisms. It is thought to occur due to abnormal pressure or mechanical stress chronically applied to the foot, usually with concomitant predisposing conditions such as peripheral sensory neuropathy, peripheral motor neuropathy, autonomic neuropathy or peripheral arterial disease. It is a major complication of diabetes mellitus, and it is a type of diabetic foot disease. Secondary complications to the ulcer, such as infection of the skin or subcutaneous tissue, bone infection, gangrene or sepsis are possible, often leading to amputation.

Micropore particle technology consists of fine, highly porous particles that remove fluid by a combination of capillary action and evaporation. Currently, they are mainly used in wound healing, where they absorb wound exudate into their micropore structure. Here capillary flow transports the exudate away from the wound surface towards the upper surface of the MPPT layer, where a highly expanded surface area facilitates effective evaporation. The MPPT essentially acts as small micro-pumps, which, due to their small size, are able to access all crevices in the wound surface.

<span class="mw-page-title-main">Quantitative sensory testing</span> Tests for somatosensory function

Quantitative sensory testing (QST) is a panel of diagnostic tests used to assess somatosensory function, in the context of research and as a supplemental tool in the diagnosis of somatosensory disorders, including pain insensitivity, painless and painful neuropathy. The panel of tests examine a broad range of different sensations, including hot, cold, touch, vibration. It has both positive and negative tests. QST reflects a formalisation of existing neurological tests into a standardised battery designed to detect subtle changes in sensory function. Large datasets representing normal responses to sensory tests have been established to quantitate deviation from the mean and allow comparison with normal patients. It is thought that a detailed evaluation of somatosensory function may be useful in identifying subtypes of pain and as a potential tool to identify asymptomatic neuropathy, which may represent up to 50% of total people with neuropathy. In clinical use, it is often combined with other tests such as clinical electrophysiology. In research settings it is increasingly applied in combination with advanced imaging such as fMRI, epidermis "nerve" biopsies and microneurography to classify subtypes of painful disorders.

<span class="mw-page-title-main">Diabetic foot infection</span> Medical condition

Diabetic foot infection is any infection of the foot in a diabetic person. The most frequent cause of hospitalization for diabetic patients is due to foot infections. Symptoms may include pus from a wound, redness, swelling, pain, warmth, tachycardia, or tachypnea. Complications can include infection of the bone, tissue death, amputation, or sepsis. They are common and occur equally frequently in males and females. Older people are more commonly affected.

<span class="mw-page-title-main">Integra LifeSciences</span> Device manufacturing company

Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.

References

  1. 1 2 Margolis, David J; Malay, D Scot; Hoffstad, Ole J; Leonard, Charles E; MaCurdy, Thomas; Nava, Karla López de; Tan, Yang; Molina, Teresa; Siegel, Karen L (17 February 2011). "Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008". Agency for Healthcare Research and Quality (US). PMID   22049565 . Retrieved 6 July 2024.
  2. ↑ Armstrong, D.G., et al., It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. Clin Infect Dis, 2004. 39 Suppl 2: p. S92–9.
  3. ↑ Raspovic, A. and K.B. Landorf, A survey of offloading practices for diabetes-related plantar neuropathic foot ulcers. J Foot Ankle Res, 2014. 7: p. 35.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 Snyder, Robert J.; Frykberg, Robert G.; Rogers, Lee C.; Applewhite, Andrew J.; Bell, Desmond; Bohn, Gregory; Fife, Caroline E.; Jensen, Jeffrey; Wilcox, James (1 November 2014). "The Management of Diabetic Foot Ulcers Through Optimal Off-Loading". Journal of the American Podiatric Medical Association. 104 (6): 555–567. doi:10.7547/8750-7315-104.6.555. ISSN   8750-7315.
  5. 1 2 Armstrong, David G.; Nguyen, Hienvu C.; Lavery, Lawrence A.; van Schie, Carine H.M.; Boulton, Andrew J.M.; Harkless, Lawrence B. (1 June 2001). "Off-Loading the Diabetic Foot Wound". Diabetes Care. 24 (6): 1019–1022. doi: 10.2337/diacare.24.6.1019 . ISSN   0149-5992.
  6. ↑ Lavery, L.A., et al., Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations: a comparison of treatments. Diabetes Care, 1996. 19: p. 818–821.
  7. 1 2 Lewis, Jane; Lipp, Allyson (31 January 2013). "Pressure-relieving interventions for treating diabetic foot ulcers". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD002302.pub2.
  8. 1 2 Birke, J.A.; Patout Jr, C.A. (1 March 2000). "The Contact Cast: An Update and Case Study Report". Wounds: a Compendium of Clinical Research and Practice. 12 (2). HMP Communications, LLC: 26–31. ISSN   1044-7946 – via ResearchGate.
  9. ↑ Boulton, A.J., Diabetic foot--what can we learn from leprosy? Legacy of Dr Paul W. Brand. Diabetes Metab Res Rev, 2012. 28 Suppl 1: p. 3-7.
  10. ↑ Schmidt, V.E., J.H. Somerset, and R.E. Porter, Mechanical properties of orthopedic plaster bandages. J Biomech, 1973. 6(2): p. 173-85.
  11. ↑ Kowalski, K.L., J.D. Pitcher, Jr., and B. Bickley, Evaluation of fiberglass versus plaster of Paris for immobilization of fractures of the arm and leg. Mil Med, 2002. 167(8): p. 657-61.
  12. ↑ Greenhagen, R.M. and D.K. Wukich, Total contact casting for neuropathic ulcers: a lost art? J Diabetic Foot Complications, 2009. 1(4): p. 2-9.
  13. ↑ Fife C.E. et al., Diabetic foot ulcer off-loading: The gap between evidence and practice. Data from the US Wound Registry. Adv Skin Wound Care. 2014 Jul;27(7):310-6.
  14. ↑ "Home". uswoundregistry.com.
  15. ↑ Capobianco, C.M., J.J. Stapleton, and T. Zgonis, The role of an extended medial column arthrodesis for Charcot midfoot neuroarthropathy. Diabet Foot Ankle, 2010. 1.
  16. ↑ Jimenez A, "Total Contact Casting," in Update 2003, p 282, The Podiatry Institute, Decatur, GA, 2003.
  17. ↑ Wertsch, J.J., et al., Plantar pressures with total contact casting. J Rehabil Res Dev, 1995. 32(3): p. 205-9.
  18. ↑ Bloomgarden, Z.T., American Diabetes Association 60th Scientific Sessions, 2000: the diabetic foot. Diabetes Care, 2001. 24(5): p. 946-51.
  19. ↑ Morona, J.K., et al., Comparison of the clinical effectiveness of different off-loading devices for the treatment of neuropathic foot ulcers in patients with diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev, 2013. 29(3): p. 183-93.
  20. ↑ Mueller, M.J., et al., Effect of Achilles tendon lengthening on neuropathic plantar ulcers. A randomized clinical trial. J Bone Joint Surg Am, 2003. 85-a(8): p. 1436-45.
  21. ↑ Piaggesi, A., et al., An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast. Diabetes Care, 2007. 30(3): p. 586-90.
  22. ↑ Van De Weg, F.B., D.A. Van Der Windt, and A.C. Vahl, Wound healing: total contact cast vs. custom-made temporary footwear for patients with diabetic foot ulceration. Prosthet Orthot Int, 2008. 32(1): p. 3-11.
  23. ↑ Mueller, M.J., et al., Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial. Diabetes Care, 1989. 12(6): p. 384-8.
  24. ↑ Caravaggi, C., et al., Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diabetes Care, 2000. 23(12): p. 1746-51.
  25. 1 2 Lavery, Lawrence A; Higgins, Kevin R; La Fontaine, Javier; Zamorano, Ruben G; Constantinides, George P; Kim, Paul J (2015). "Randomised clinical trial to compare total contact casts, healing sandals and a shear‐reducing removable boot to heal diabetic foot ulcers". International Wound Journal. 12 (6): 710–715. doi: 10.1111/iwj.12213 . ISSN   1742-4801. PMC   7950500 . PMID   24618113.
  26. ↑ "Integra LifeSciences Acquirers Derma Sciences for $204M, Expands Regenerative Technology Offerings". www.meddeviceonline.com. Retrieved 2021-10-01.
  27. ↑ "UPDATE 1-Derma Sciences to buy MedEfficiency for $14.5 mln". Reuters. 2012-03-29. Retrieved 2021-10-01.
  28. ↑ Arnold, Jonathan F.; Marmolejo, Valerie (October 2017). "Outcomes Achieved With Use of a Prefabricated Roll-On Total Contact Cast". Foot & Ankle International. 38 (10): 1126–1131. doi:10.1177/1071100717716486. ISSN   1944-7876. PMID   28800712. S2CID   40470722.
  29. ↑ "New Products and Industry News". www.hmpgloballearningnetwork.com. August 2017. ISSN   1943-2720. Archived from the original on 2021-10-01. Retrieved 24 May 2023.
  30. ↑ "Swedish Takeover: Plaster Maker BSN Sold for $2.8 Billion". www.handelsblatt.com. Retrieved 2021-10-01.
  31. ↑ Snyder, R.J. and K.K. Lanier, Offloading difficult wounds and conditions in diabetic patient. Ostomy Wound Manage, 2002. 48(1): p. 22-8, 30, 32-5.
  32. ↑ Bus, S.A., et al., The effectiveness of footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in diabetes: a systematic review. Diabetes Metab Res Rev, 2008. 24 Suppl 1: p. S162-80.
  33. ↑ Greenhagen, R., Complications of total contact casting: the benefits of using TCC still far outweigh any risks. Podiatry Management, 2012, June/July: p. 153-8.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.